The EMA had also previously advised against using daclizumab in patients with pre-existing hepatic disease or hepatic impairment, or patients with autoimmune diseases other than MS. They had also ...

Kato et al., therefore, compared steroid-free maintenance using daclizumab with corticosteroid maintenance in HCV-infected liver transplant recipients. In part 1 of the study (1999–2001), 50 ...